Opka Health - Super Growth
Long Only, Momentum, Portfolio Strategy
Seeking Alpha Analyst Since 2009
Jim Van Meerten writes on financial subjects here and on Barchart Portfolio Blogs and Seeking Alpha. He earned a BS in Accounting and Business Administration from Berry College; a Juris Doctorate from the Woodrow Wilson School of Law; and attended post-baccalaureate and graduate courses in Business Administration, Quantitative Math, and Education at Florida Atlantic University, Georgia State University and University of North Carolina at Charlotte. In the past he has been an accountant, attorney, adjunct professor in Business Law, Accounting and Internal Auditing, financial advisor, supervisory principal, and compliance officer. He also passed the Georgia CPA Exam, the Certified Internal Auditor Exam, and the FINRA Series 7, 24 and 9/10 exams.He is presently also a contributor on MSN Top Stocks Blog, Motley Fool and is a member of the M100 on Marketocracy, an elete honor chosen by the editors of Marketocracy as being in the top 100 portfolio managers of over 100,000 portfoiios they review. He would enjoy hearing your comments at JimVanMeerten@gmail.com.
- 100% technical buy signals.
- 6 new highs and up 53.95% in the last month.
- 180.93% gain in the last year.
The Barchart Chart of the Day belongs to the diagnostic and pharmaceutical company Opka Health (OPK). I found the stock by first using Value Line to screen for stocks their analysts predict will have a 25% annual growth rate of Revenue over the next 5 years. I then used Barchart to sort that list first by the highest Weighted Alpha then used the Flipchart function to review the charts for consistent price appreciation.. Since the Trend Spotter signaled a buy on 6/8 the stock gained 101.85%.
Opko Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. Opko Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.
Barchart technical indicators:
- 100% technical buy signals
- 233.90+ Weighted Alpha
- 180.93% gain in the last year
- Trend Spotter buy signals
- Above its 20, 50 and 100 day moving averages
- 6 new highs and up 53.95% in the last month
- Relative Strength Index 61.72%
- Technical support level at 5.34
- Recently traded at 5.45 with a 50 day moving average of 3.66
- Market Cap $3.59 billion
- Revenue expected to grow 42.30% this year and another 14.40% next year
- Earnings estimated to increase 108.10% this year, 700.00% next year and continue to compound at an annual rate of 12.00% for the next 5 years
- Wall Street analysts issued 2 strong buy, 2 buy and 2 hold recommendations on the stock
- The individual investors following the stock on Motley Fool voted 245 to 29 that the stock will beat the market
- 33,600 investors are monitoring the stock on Seeking Alpha
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.